Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 5/2023

Open Access 06-02-2023 | Pancreatectomy | ASO Author Reflections

ASO Author Reflections: The Safety and Efficacy of Robot-Assisted and Laparoscopic Distal Pancreatectomy in Patients with Resectable Left-Sided Pancreatic Cancer

Authors: Tess M. E. van Ramshorst, MD, Jeffrey W. Chen, MD, Mohammad Abu Hilal, MD, PhD, Marc G. Besselink, MD, PhD

Published in: Annals of Surgical Oncology | Issue 5/2023

Login to get access

Excerpt

Minimally invasive distal pancreatectomy (MIDP), consisting of both laparoscopic distal pancreatectomy (LDP) and robot-assisted distal pancreatectomy (RDP), is considered the preferable approach for benign lesions of the pancreatic body and tail, as also supported by two randomized trials.1,2 Lately, the indications of MIDP are broadening to malignant lesions3 and the use of the robot-assisted approach is emerging. Although several retrospective studies have compared LDP and open distal pancreatectomy (ODP) in patients with pancreatic cancer,4 studies assessing the safety and efficacy of RDP and LDP in patients with left-sided pancreatic cancer are lacking. …
Literature
1.
Bjornsson B, Larsson AL, Hjalmarsson C, Gasslander T, Sandstrom P. Comparison of the duration of hospital stay after laparoscopic or open distal pancreatectomy: randomized controlled trial. Br J Surg. 2020;107(10):1281–8.CrossRefPubMed
2.
de Rooij T, van Hilst J, van Santvoort H, et al. Minimally invasive versus open distal pancreatectomy (LEOPARD): a multicenter patient-blinded randomized controlled trial. Ann Surg. 2019;269(1):2–9.CrossRefPubMed
3.
Abu Hilal M, Richardson JR, de Rooij T, Dimovska E, Al-Saati H, Besselink MG. Laparoscopic radical “no-touch” left pancreatosplenectomy for pancreatic ductal adenocarcinoma: technique and results. Surg Endosc. 2016;30(9):3830–8.CrossRefPubMed
4.
van Hilst J, de Rooij T, Klompmaker S, et al. Minimally invasive versus open distal pancreatectomy for ductal adenocarcinoma (DIPLOMA): a pan-European propensity score matched study. Ann Surg. 2019;269(1):10–7.CrossRefPubMed
5.
Metadata
Title
ASO Author Reflections: The Safety and Efficacy of Robot-Assisted and Laparoscopic Distal Pancreatectomy in Patients with Resectable Left-Sided Pancreatic Cancer
Authors
Tess M. E. van Ramshorst, MD
Jeffrey W. Chen, MD
Mohammad Abu Hilal, MD, PhD
Marc G. Besselink, MD, PhD
Publication date
06-02-2023
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology / Issue 5/2023
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-023-13171-6

Other articles of this Issue 5/2023

Annals of Surgical Oncology 5/2023 Go to the issue

ASO Author Reflections

ASO Author Reflections: Evolution of Surgical Techniques Through Robotic Surgery Technology

Gastrointestinal Oncology

Timeliness in Cancer Care from the Patient Perspective

ASO Visual Abstract

ASO Visual Abstract: Impact of Age on Treatment and Survival in Esophagogastric Cancer

ASO Visual Abstract

ASO Visual Abstract: Symptom Trajectories Informing Patient Care After Lung Cancer Surgery: A Longitudinal Patient-Reported Outcome Study

ASO Visual Abstract

ASO Visual Abstract: The Prognostic Value of Preoperative Serum Markers and Risk Classification for Patients with Hepatocellular Carcinoma

ASO Visual Abstract

ASO Visual Abstract: Hepatectomy Following Conversion Therapy Using Tyrosine Kinase Inhibitors Plus Anti-PD-1 Antibody Therapy in Patients with Unresectable Hepatocellular Carcinoma